American Association for Cancer Research
Browse
00085472can090049-sup-sfigs_1-3.pdf (155.04 kB)

Supplementary Figures 1-3 from Cetuximab/C225-Induced Intracellular Trafficking of Epidermal Growth Factor Receptor

Download (155.04 kB)
journal contribution
posted on 2023-03-30, 18:51 authored by Hong-Jun Liao, Graham Carpenter
Supplementary Figures 1-3 from Cetuximab/C225-Induced Intracellular Trafficking of Epidermal Growth Factor Receptor

History

ARTICLE ABSTRACT

The monoclonal antibody C225 interacts with the ectodomain of the epidermal growth factor (EGF) receptor (EGFR) to block ligand binding and initiates receptor endocytosis and intracellular trafficking. The data herein show that C225-dependent EGFR trafficking relocalizes the receptor to the endoplasmic reticulum (ER) and nucleus. This mechanism, which also involves interaction of the C225-internalized receptor with the Sec61 translocon within the ER, is, in most respects, analogous to the pathway previously described for EGF-induced trafficking to the ER and nucleus. However, although inhibition of receptor tyrosine kinase activity blocks EGF-induced nuclear localization of the receptor, the same kinase inhibitors stimulate C225-dependent nuclear localization of EGFR in the nucleus. In contrast, the kinase inhibitor Lapatinib fails to stimulate nuclear accumulation of the receptor in C225-treated cells and does not provoke receptor dimerization as do inhibitors that recognize the open conformation of the receptor kinase. This suggests that inhibitor-dependent receptor dimerization may facilitate C225-induced receptor trafficking. [Cancer Res 2009;69(15):6179–83]

Usage metrics

    Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC